Remaining in the field of hematological pathologies, Guillerey et al. demonstrated in TIGIT deficient mice with multiple myeloma, a decrease in monoclonal component associated with reduced tumor burden and prolonged survival. The gene discussed is TIGIT; the disease is plasma cell myeloma.